Immunoassay services based on Simoa platform, 5/15

May 2015—Myriad RBM launched immunoassay services based on Quanterix’s ultrasensitive Simoa (single molecule array) platform, which enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.

Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The company has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 and tumor necrosis factor alpha, which are available from its CLIA-certified laboratory in Austin, Tex. Each assay includes carefully designed calibrators and controls to provide multiple measurements of quality, precision, and accuracy.

Myriad RBM, 512-835-8026